Embedded Files
2022: First in human clinical trial of imvalvSP (pending approval by Argentina regulatory agency - ANMAT)
2022: First in human clinical trial of imvalvSP (pending approval by Argentina regulatory agency - ANMAT)
iMvalv Presentation at
iMvalv Presentation at
Ophthalmology Futures European Forum
Ophthalmology Futures European Forum
Fairmont Rey Juan Carlos 1 Hotel, Barcelona
3 September 2015
13:40-14:45
Company Presentations
13:40-13:47 Company: Implandata Ophthalmic Products GmbH, Max G Ostermeier Co-Founder and General Manager
13:47 – 13:54 .Company: Sensimed AG | David Bailey, Chief Executive Officer and Board Member
13:54 – 14:01 Company: iMvalv | Fabio Guarnieri, Chief Executive Officer
14:01 – 14:08 .Company: iOPtima Ltd | Ronen Castro, Chief Executive Officer
14:08 – 14:15 .Company: Innfocus Inc. | Russ Trenary, President and Chief Executive Officer
14:15 – 14:22 .Company: Aquesys Inc. | Ron Bache, President and Chief Executive Officer
14:22 – 14:29 .Company: Ivantis | Dave Van Meter, Chairman, President and Chief Executive Officer
14:29 – 14:36 Company: Transcend Medical Inc. | Brian Walsh, President and Chief Executive Officer
14:36 – 14:45 Summary
PROYECTOS SELECCIONADOS PROGRAMA CITES STARTUPS 2015
PROYECTOS SELECCIONADOS PROGRAMA CITES STARTUPS 2015
El Centro de Innovación Tecnológica, Empresarial y Social seleccionó los proyectos a participar de la edición 2015 de CITES Startups, un programa de cuatro meses de aceleración de Startups tecnológicas. A través de este exigente programa los emprendedores participan de cursos de capacitación, exposición a mentores de negocios y acceso a tecnólogos de primer nivel, para competir por ser invertidos e incubados dentro de CITES.
En esta edición, se recibieron inscripciones de 115 proyectos provenientes de diversos puntos del país, Latinoamérica, Estados Unidos y Europa. La distribución por áreas de los proyectos fue la siguiente: 3 de Nanotecnología, 17 de Biotecnología, 36 de Ingenierías y 59 de TICs. De los proyectos presentados, y luego de un exhaustivo análisis, fueron seleccionados los siguientes cinco emprendimientos: SILK FOR ALL, VIEWMIND, NANOTICA, IMVALV Y MZP TECNOLOGIA.
ARVO 2015 Poster "Hot Topic"
ARVO 2015 Poster "Hot Topic"
Best scientific poster in XX Congreso Argentino de Oftalmología
National Minister of Science and Technology was gifted an iMvalv from Entre Rios Governor.
National Minister of Science and Technology was gifted an iMvalv from Entre Rios Governor.
ARVO 2014 Annual Meeting Abstracts
ARVO 2014 Annual Meeting Abstracts
Poster Program Number: 4635 Poster Board Number: A0203
Presentation Time: 11:00 AM–12:45 PM
ARVO Foundation for Eye Research
ARVO Foundation for Eye Research
Vision Innovation and Venture Forum
Vision Innovation and Venture Forum
MAY 03, 2013
MAY 03, 2013
SEATTLE, WASHINGTON
SEATTLE, WASHINGTON
Part 2: Researcher presentations and panel discussion
Device and technology innovations
Page updated
Report abuse